PT -期刊文章AU -乌尔里希,西尔维亚AU -萨克斯r, Stéphanie AU - Hasler, Elisabeth D. AU - Schwarz, Esther I. AU - Schneider, Simon R. AU - Furian, Michael AU - Bader, Patrick R. AU - Lichtblau, Mona AU - Bloch, Konrad E. TI - Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial AID - 10.1183/13993003.002762019 DP - 2019 Aug 01 TA - European Respiratory Journal PG - 1900276 VI - 54 IP - 2 4099 - //www.qdcxjkg.com/content/54/2/1900276.short 4100 - //www.qdcxjkg.com/content/54/2/1900276.full SO - Eur Respir J2019 Aug 01; 54 AB - Study question We investigated whether domiciliary oxygen therapy (DOXT) increases exercise capacity and quality of life in patients with pulmonary arterial or distal chronic thromboembolic pulmonary hypertension (PAH/CTEPH) presenting with mild resting hypoxaemia and exercise-induced oxygen desaturation.Materials and methods 30 patients with PAH/CTEPH, mean±sd age 60±15 years, pulmonary artery pressure 39±11 mmHg, resting arterial oxygen saturation measured by pulse oximetry (SpO2) ≥90%, SpO2 drop during a 6-min walk test ≥4%, on pulmonary hypertension-targeted medication, were randomised in a double-blind crossover protocol to DOXT and placebo (ambient air) treatment, each over 5 weeks, at 3 L·min−1 via nasal cannula overnight and when resting during the day. Treatment periods were separated by 2 weeks of washout. Co-primary outcomes were changes in 6-min walk distance (6MWD, breathing ambient air) and physical functioning scale of the 36-item short-form medical outcome questionnaire during treatment periods.Results DOXT increased the 6MWD from baseline 478±113 m by a mean (95% CI) of 19 (6–32) m, and physical functioning from 52±29 by 4 (0–8) points. Corresponding changes with placebo were 1 (−11–13) m in 6MWD and −2 (−6–2) points in physical functioning. Between-treatment differences in changes were 6MWD 18 (1–35) m (p=0.042) and physical functioning 6 (1–11) points (p=0.029). DOXT significantly improved the New York Heart Association functional class versus placebo.Answer to the question This first randomised trial in PAH/CTEPH patients with exercise-induced hypoxaemia demonstrates that DOXT improves exercise capacity, quality of life and functional class. The results support large long-term randomised trials of DOXT in PAH/CTEPH.Domiciliary oxygen therapy improves 6-min walk distance and quality of life in patients with precapillary pulmonary hypertension who desaturate during exercise, and should thus be considered as an adjunct to medical therapy http://bit.ly/2M8H4iq